Browsing: Biotech

A Life Transformed: Noland‍ Arbaugh’s ⁢Journey with Neuralink The Accident That Changed Everything In 2016, Noland Arbaugh’s life took a…

Pioneering Pig Kidney Transplant Recipient Passes Away at 62 Richard “Rick” Slayman, the groundbreaking patient who underwent a genetically modified…

Revolutionizing Blood Transfusions: The Potential ⁢of Artificial Platelets The Scarcity of Platelets Platelets, the cell fragments crucial for blood clotting,…

Unprecedented Avian Influenza Outbreak Raises Concerns⁣ Among Experts CDC ‍Urges Vigilance Following Human H5N1 Case in Texas Last Friday, a…

Revolutionizing Cancer Treatment: The Potential of Crystallizing Drugs in Space The Challenges of Immunotherapy Drug Administration Immunotherapy has emerged as…

Pioneering Pig Kidney Transplant Offers Hope for Organ Shortage In an unprecedented medical breakthrough, a team of surgeons at Massachusetts…

The Quest for Longevity: Insights from a Nobel Laureate Throughout history, the wealthy⁢ have sought ways to extend their lives.…

For years, a type of bacteria called Enterococcus faecium lurked in Lynn Cole’s bloodstream. Often found in hospitals, E. faecium is usually a gut-dwelling bacteria but can creep into other areas of the body. Her doctors tried various antibiotics, but the bacteria was zombie-like: It kept coming back. Running out of options after a month-long

23andMe has been a lot of things throughout its history. Founded in 2006, ” after a “. Valued at $6 billion in 2021 when it went public, 23andMe now risks being delisted from the Nasdaq as its stock continues to trade below $1 a share.”And like many Silicon Valley startups, it’s still working out how